Heparin Market Trends Technology Innovation, Analysis Application 2028 | Key Players: TouchPoints, Chemicals

The global heparin market size is expected to reach USD 7.55 Billion in 2028 at a CAGR of 1.4% during the forecast period, according to the latest report by Reports and Data. Rising demand for heparin due to high prevalence of chronic conditions such as last-stage renal disease, atrial fibrillation, and cardiovascular diseases, increasing number of surgical procedures performed across the globe, and extensive R&D activities to explore other clinical and therapeutic roles of heparin are key factors expected to drive market revenue growth over the forecast period. In addition, heparin is used for various off-label indications in hospitals and for treatment and prevention of venous thromboembolism events in post-surgical patients, and this is another factor expected to contribute to revenue growth of the market going ahead.

Heparin is a widely used anticoagulant that significantly reduces clotting risks and thromboembolism events after major surgical interventions. Heparin is a naturally occurring polysaccharide belonging to the family of glycosaminoglycans that are primarily present in mast cell. Heparin exerts anticoagulant properties by binding to antithrombin and enhancing the subsequent inhibitory effect of antithrombin on thrombin and activated factor X. The currently available heparin is mostly obtained from animal tissue. However, due to growing concerns regarding animal safety, several approaches for bioengineering heparin such as microbial production and chemoenzymatic modification among others are increasingly being researched on. Major players are also focusing on R&D for its potential clinical and therapeutic applications such as anti-inflammatory and anti-tumor activities as well as role in prevention of infectious diseases, besides its use as an anticoagulant. Heparin has antineoplastic properties along with anticoagulant properties, and this is expected to result in increasing research activities to explore potential of heparin for treating various other conditions. This, in turn, is expected to significantly contribute to market revenue growth going ahead.

Venous thromboembolism prophylaxis with anticoagulant therapy is often used for cancer patients who are hospitalized or undergoing chemotherapy. However, possible risks of bleeding with the use of heparin and its derivatives have limited its use in management of cancer patients in other therapeutic settings, and this could hamper market growth to a certain extent over the forecast period.

For More Industry Insight, Request Sample@ https://www.reportsanddata.com/download-summary-form/4154

Some Key Highlights from the Report:

  • Low-molecular-weight heparin (LMWH) segment is expected to account for largest revenue share over the forecast period, attributable to increasing preference for LMWH over unfractionated heparin in clinical settings, in treatment of venous thromboembolism events, and in obstetrics due to low risk of bleeding and other complications associated with it.
  • Subcutaneous route of administration is expected to register significant revenue growth during the forecast period, owing to growing preference for subcutaneous therapy of heparin, lesser incidence of pain and higher patient comfort, and low risk of recurrent thromboembolism when treated with subcutaneous injection of low-molecular weight heparin.
  • Venous thromboembolism is expected to dominate other application segments between 2021 and 2028 owing to increasing incidence of VTE among post-operative patients and rising need for anticoagulant therapy with low-molecular weight heparin.
  • Hospital pharmacies segment is expected to register steady revenue CAGR over the forecast period, attributable to increasing hospital admission of patients needing surgeries or dialysis, availability of high-quality heparin derivatives, growing number of outpatient procedures, and increasing reliance on pharmacists and doctors.
  • North America is expected to account for a significantly large revenue share over the forecast period, attributable to rising incidence of cardiovascular diseases and chronic illnesses, rising number of surgical procedures performed, availability of high-end medical facilities and medications, and robust presence of key players in the market.
  • Major companies profiled in the market report include Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sanofi SA, B. Braun Melsungen AG, GlaxoSmithKline PLC, LEO Pharma A/S, Aspen Holdings, Fresenius SE & Co. KGaA, and Viatris Inc.

Request For Custom Research @ https://www.reportsanddata.com/request-customization-form/4154

eports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

Head of Business Development

Reports And Data | Web: https://www.reportsanddata.com/

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

LinkedIn | Twitter | Blogs

You may also like...

Leave a Reply

Your email address will not be published.